- Home
- CHPT vs YARW Comparison
CHPT vs YARW Comparison
Compare CHPT & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHPT | YARW |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.0M | 114.6M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CHPT | YARW |
|---|---|---|
| Price | $7.93 | $19.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $7.50 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 1.2M | 150.3K |
| Earning Date | 09-02-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $411,224,000.00 | N/A |
| Revenue This Year | $7.92 | N/A |
| Revenue Next Year | $13.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.44 | $18.24 |
| 52 Week High | $12.61 | $44.28 |
Technical Indicators
Market Signals| Indicator | CHPT | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 31.09 |
| Support Level | $5.50 | N/A |
| Resistance Level | $8.47 | $32.89 |
| Average True Range (ATR) | 0.57 | 2.00 |
| MACD | -0.30 | -0.25 |
| Stochastic Oscillator | 0.39 | 15.61 |
Price Performance
Historical ComparisonAbout CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.